Background: Navi Mumbai-Panvel's DM Package cohort (n=10), while small, includes patients with complex comorbidities (DM+CAD, DM+IHD, multi-system disease) and 100% medication reduction documentation. This pilot analysis evaluates protocol efficacy in a complex, high-cardiovascular-risk diabetic population. Objective: To evaluate the effect of the Madhavbaug CDC Panchakarma-based multimodal protocol on glycaemic, anthropometric, cardiometabolic, and medication parameters exclusively in DM Package patients (n=10) at the Navi Mumbai (Panvel) Central RIC clinic. Methods: Retrospective observational study. 10 T2DM patients enrolled in the DM Package at Navi Mumbai (Panvel) Central RIC. Only DM Package care plans (CDC-SP Base/1/2/3, CDC-KP Base/1/2/3, DM-HTN 1/2/3) included. Paired Student's t-test (two-tailed) for within-group pre–post comparisons (p<0.05 significant). Descriptive statistics as mean ± SD. Results: RBS reduced significantly from 229.80±81.28 to 142.40±44.58 mg/dL (Δ −87.40 mg/dL, −38.0%, p<0.001, n=10). Weight fell by −4.78 kg (−6.4%, p=0.002). BMI −2.02 kg/m² (−6.9%, p=0.003). Abdominal girth −4.90 cm (−5.0%, p=0.003). DBP −5.40 mmHg (−6.1%, p=0.033). Total cholesterol showed a clinically meaningful reduction of −35.40 mg/dL (−18.1%, p=0.069, n=8). Triglycerides reduced by −27.05 mg/dL (−10.4%, p=0.040, n=8). All 10 patients achieved partial medication reduction (100% partial medication reduction rate). Conclusion: Despite its small sample (n=10), Navi Mumbai-Panvel's DM Package demonstrates exceptional results: RBS −38.0% (p<0.001), weight −6.4% (p=0.002), BMI −6.9% (p=0.003), abdominal girth −5.0% (p=0.003), triglycerides −10.4% (p=0.040), and DBP −6.1% (p=0.033). The 100% partial medication reduction rate and clinically meaningful lipid trends represent the strongest combined anthropometric and pharmacoeconomic outcomes in the Central RIC DM network.
Dr. Rohit Sane1, Dr. Gurudatta Amin2, Dr. Pravin Ghadigaonkar3, Dr. Nilesh Kulthe*4, Dr. Priyanka Salwade5 (2026) studied this question.